Health plan leaders are asking a consistent set of questions: why pharmacy spend continues to rise despite increasingly sophisticated benefit design, why existing tools aren’t consistently influencing decisions at the point of prescribing, and where real, actionable savings are actually being left on the table. A related challenge is understanding how to drive better medication decisions earlier in the care journey without adding friction for members or providers. We’re bre

Dr. Paul S. Bradley, MD As Scripta's Chief Medical Officer and an actively practicing clinician currently participating in GLP-1 clinical trials, I've had a front-row seat to one of the most significant shifts in obesity medicine in decades. GLP-1 pills are dominating headlines right now, and while the excitement is warranted, there's a lot of nuance in the data that aren’t necessarily in the headlines. Here's my honest take on what's working, what's being misunderstood,

By Miriam Paramore, Founder & CEO of RxUtility There's never been more "transparency" in prescription drug pricing – and in some ways, plan sponsors have never been more confused. That's not a coincidence. After 35 years in healthcare technology and drug pricing policy, I've watched every transparency initiative promise to finally make the system legible for employers. And each time, the data got bigger, the reports got longer, and the fundamental question got harder to a

Modern pharmacy benefits are sophisticated by design. PBMs manage enormous networks, negotiate rebates, build formularies, and administer claims for millions of members across thousands of plan designs. It's a complex, high-volume operation — and while some may think it works, that kind of complexity creates blind spots. In pharmacy benefits, those blind spots tend to show up in the same places: the gap between what a member pays at the counter and what they could pay with a

Every benefits vendor promises a seamless implementation. Few deliver. If you've been in HR and benefits long enough, you know the drill: the sales experience is polished, the demos are impressive, and somewhere between contract signing and go-live, things get complicated. Suddenly you're the project manager for a solution you just bought. Meetings multiply. Decisions pile up. Your team absorbs the lift. Pharmacy benefits is already one of the most complex categories you

As we move through 2026, several high-profile medications are entering the market, promising new options for patients across a range of conditions. We sat down with Dr. Paul Bradley, Chief Medical Officer at Scripta Insights, to get his perspective on just how game-changing these drug launches could be for patients, plan sponsors, and the bigger healthcare landscape. The GLP-1 Competition Heats Up The GLP-1 market continues to dominate headlines, and new drugs from Novo Nordi